Definition
1,3-Benzenedicarboxylic acid, polymer with 5-amino-1,3,3-trimethylcyclohexanemethanamine, nonanedioic acid and cyclohexylamine
Cosmetic roles
Leaves a thin film where appliedFILM FORMING
Safety & regulatory references
Not classified under Korea’s toxic-substance GHS list · existing chemical substance
Other restriction: ban substances that deplete the ozone layer
Source: EU CosIng ingredient list
More data — names, identifiers, properties, test records, literature
Official labels & definitions
JCIA labelling name (イソホロンジアミン/シクロヘキシルアミン/イソフタル酸/アゼライン酸)コポリマー: 本品は、イソホロンジアミン、シクロヘキシルアミン、イソフタル酸とアゼライン酸の共重合体である。
Source: JCIA labelling names (Japan)
Names & identifiers
ISOPHORONE DIAMINE/CYCLOHEXYLAMINE/ISOPHTHALIC ACID/AZELAIC ACID COPOLYMERINCI1,3-Benzenedicarboxylic acid, polymer with 5-amino-1,3,3-trimethylcyclohexanemethanamine and nonanedioic acid, cyclohexylamine, modifiedSynonym(イソホロンジアミン/シクロヘキシルアミン/イソフタル酸/アゼライン酸)コポリマーJapanese labelling name
- CAS No.chemical registry number
- 68584-15-6
- DTXSIDUS EPA chemical ID
- DTXSID7099890
What products actually use it for
What the 1 products reported to the US EPA with this ingredient use it for. Products outside cosmetics are included, so the top few rows are its main uses.
- Film former1
Source: US EPA CompTox dashboard
Related literature
- Treatment of Refractory Centrofacial Melasma in a 64-Year-Old Female Using the NewMelan Depigmentation System: A Case Report. · 2026
- The Treatment of Perioral (Periorificial) Dermatitis With Topical Roflumilast 0.3% Cream: An Illustrative Case Study With Rapid Onset and Prolonged Remission. · 2026
- Efficacy and safety of a novel anhydrous 0.1% retinal and 10% azelaic acid concentrate for blemish-prone skin: An eight-week randomized prospective split-face, vehicle-controlled study. · 2026
- International Expert Consensus on Integrated Skincare Active Ingredients for Pretreatment and Posttreatment Use With Medical Aesthetic Procedures to Enhance Skin Benefits. · 2026
- Post-inflammatory Hyperpigmentation in Skin of Color: Emerging Therapies and Treatment Algorithms. · 2026